AI-powered tumor classifier to be presented at CTOS 2025

🧠 Advancing Brain Metastases Research at ESMO 2025 Berlin hosted the largest European oncology congress organized by the European Society for Medical Oncology (ESMO) – attracting around 35,000 participants and serving as one of the most influential international platforms for oncology exchange. We are proud that Univ.-Prof. Julia Furtner-Srajer from the Research Center for Medical Image Analysis and Artificial Intelligence (MIAAI) at Danube Private University Austria (DPU) was invited to speak in the session: 💡 “Innovations in the management of newly diagnosed and progressive brain metastases.” Her lecture: 🎤 “Evaluation tumor response in brain metastases” Prof. Furtner-Srajer’s contribution advances the global discussion on innovative approaches to assessing tumor response in brain metastases. 🔍 #DPU #ESMO2025 #Oncology #MedicalImaging #ArtificialIntelligence #ResearchExcellence

We’re happy to welcome Prof. Xavier Matias-Guiu to the Onco AI-Med alliance, Indivumed’s advisory board and initiative to advance precision oncology. Prof. Matias-Guiu is heading the Pathology Institute of the University of Lleida, a leading expert in gynecologic pathology and has been supporting Indivumed building our multi-omics database for several years. Recently, he has been appointed as President of the European Society of Pathology (ESP). Xavier brings invaluable expertise to our collaborative network and advisory board. When joining the Onco AI-Med Advisory Board, he pointed out: “Indivumed’s Onco AI-Med Board is key to advancing precision oncology. Together, we can drive faster, deeper insights for patients.” Onco AI-Med is a global alliance of leading oncologists and cancer researchers, rooted in two decades of trusted scientific partnerships among its members and Indivumed. The network brings together experiences and perspectives of experts from different countries and backgrounds to share ideas and advance the concept of precision medicine for the benefit of cancer patients all over the world. 👉 Learn more: https://lnkd.in/eQV6QEiS #PrecisionOncology #GlobalCollaboration #CancerResearch

Our latest article, “Predicting Neoadjuvant Chemotherapy Response in Breast Cancer Using Multiparametric MRI-Based Radiomics and Machine Learning: A Systematic Review and Meta-Analysis of 1,469 Patients,” is now published in the Indian Journal of Surgical Oncology. 🧠 This study systematically reviews and analyzes how multiparametric MRI (mpMRI) combined with machine learning can accurately predict response to neoadjuvant chemotherapy (NAC) in breast cancer. 📊 Key Findings: Pooled predictive performance: AUC = 0.803 (95% CI: 0.682–0.925) Demonstrates strong potential for non-invasive, early prediction of treatment response Highlights the need for standardized imaging protocols and multicenter validation 📄 Read the full article at Springer Nature : https://lnkd.in/dXNSmHAa #BreastCancer #Radiomics #MRI #MachineLearning #ArtificialIntelligence #Oncology #PrecisionMedicine #MedicalImaging #Research

"MedExplora Weekly" 🧠 World Neuroendocrine Tumors Awareness Month Neuroendocrine tumors (NETs) are often slow-growing but notoriously elusive, leading to late diagnoses. Current therapies, such as somatostatin analogs and the targeted radiotherapy Lutetium-177 dotatate (Lu-177-DOTA-TATE), work by binding to somatostatin receptors on tumor cells and delivering localized radiation to control tumor growth. Recent research has taken this further: combining Lu-177-DOTA-TATE with triapine, a ribonucleotide reductase inhibitor that blocks DNA synthesis, significantly reduced tumor burden in preclinical NET models. This combination could enhance the effectiveness of radionuclide therapy and open new doors for patients with advanced or treatment-resistant disease. 🧬 Precision oncology is steadily turning NETs from rare and deadly into manageable conditions. Post Designer: Fatima Jamal Scientific Writer: Simon Mikaelian Further Reading: 1. https://lnkd.in/ecznwMvC #Medexplora #Neuroendocrine #Oncology #Radiotheranostics #PrecisionMedicine #MedicalInnovation #Research #Medexploraweekly

The National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer published a paper in the Journal of Clinical Oncology discussing PSMA PET imaging to study the process of biochemical recurrence and urging clinical trials. Next-gen imaging like PSMA PET can show "PSMA+BCR," which is a hidden state between local and metastatic disease," wrote Dr. Yüksel Ürün, a medical oncologist at Ankara University School of Medicine

At DeepLife, we’re collaborating with the MIRCADE (Methods and Innovations for Research in Pediatric Cancers) team at INSERM, the French national institute of public health and research, to build digital twins of tumor cells. Our goal is to enable customized and safer therapeutic strategies for children affected by hepatoblastoma, a rare but aggressive pediatric liver cancer. This initiative, launched last year, integrates multi-omic profiling, AI-driven modeling, and biological validation to simulate tumor behavior and treatment response at the cellular level. The first computational insights are now progressing into preclinical validation, a critical step in bridging in silico findings with real-world translational impact. By the end of 2026, the consortium aims to deliver a full preclinical dossier a milestone toward transforming these digital biology breakthroughs into effective, patient-centered therapies.

In a stunning medical breakthrough, scientists have discovered a way to eliminate up to 99% of cancer cells using targeted light therapy — completely avoiding chemotherapy and radiation. The process, known as photodynamic therapy (PDT), uses special light-sensitive molecules that attach only to cancer cells. When activated by a specific wavelength of light, these molecules trigger the cancer cells to self-destruct — while leaving healthy tissue untouched. This treatment not only reduces pain and side effects but also offers faster recovery and precise control over tumor elimination. Early results from clinical studies show extraordinary promise for cancers like skin, breast, and lung tumors, marking a potential revolution in oncology. Unlike traditional approaches, this therapy doesn’t poison or burn cells — it uses energy and precision instead of destruction. As researchers refine the technique, the future may hold a world where light replaces toxic drugs in the fight against cancer. The dawn of light-based medicine may be the beginning of a cancer-free future. #CancerResearch #MedicalBreakthrough #LightTherapy #ScienceNews #Oncology

Can immune-based therapy enhance traditional rectal cancer treatment? A new JAMA Network Open phase 2 trial offers early hope. Researchers tested adding ipilimumab and nivolumab, two immunotherapy drugs, to standard chemoradiotherapy before surgery in locally advanced rectal cancer. The combination was well tolerated and showed promising tumor response rates, hinting at added therapeutic benefit. Though larger trials are still needed, this study points to a future where immunotherapy and chemoradiation work hand in hand — potentially improving surgical outcomes and long-term survival for rectal cancer patients. #CancerResearch #RectalCancer #Immunotherapy #Oncology #BiohackYourself Source: https://lnkd.in/eYnfmmZM Published Date: August 21, 2025 👉 Comment BIOHACK if you want more science and health news like this! #HealthNews #ScienceNews #ResearchUpdates #Biohack Disclaimer: This content is for educational and entertainment purposes only and is not a substitute for medical advice. Always consult a healthcare professional. Full disclaimer: https://lnkd.in/eJE9Rsty 🧠 We explore all angles — ancient wisdom, modern science, and everything in between. No allegiance to Big Pharma or Big Natural. 🔍 We cite studies, but encourage you to read them, question funding, and review the methods. Stay curious. 📚 Not all journals are equal. Peer-reviewed ≠ perfect. Check the source, think critically, and decide for yourself. ⚠️ One study isn’t the full story. Science evolves. We’re here to inform, not to tell you what to believe.

The Hong Kong University of Science and Technology (HKUST) has developed SmartPath, an advanced AI pathology analysis system that achieves over 95% accuracy in diagnosing multiple prevalent cancers such as lung, breast, colorectal, and gastric cancer.🩸 Trained on more than half a million whole slide images from diverse tissue sites, SmartPath supports over 100 clinical tasks including cancer classification, biomarker quantification, treatment response assessment, and survival prediction. This breakthrough accelerates diagnostic turnaround, enhances precision, and aids personalized cancer treatment, marking a significant advancement in pathology and oncology care in the region.

Hot off the press! 🔥 Did you know that rectal tumors expel tiny blebs (called EVs) that contain energy molecules (called mtDNA) that otherwise would have fueled the cancer to spread to other organs? OxyTarget, the prospective population-based biomarker study in rectal cancer (Ahus 2013-2017), has once again delivered discoveries. This time, the talented scientists of my research group have combined functional MR imaging of the tumor with sequencing of mtDNA in plasma EVs from rectal cancer patients, which no one has managed before. Kine Mari Bakke (functional MR imaging), Tonje Bjørnetrø (plasma EV and mtDNA analyses), Paula Bousquet and Adriana Maria Sanabria (mtDNA analysis), Sebastian Meltzer (clinical trialist). Once again, huge thanks to Kathrine Røe Redalen for OxyTarget, her scientific legacy at Ahus. #liquidbiopsy #mtDNA Akershus universitetssykehus CMOR – Clinical and Molecular Oncology in ColoRectal Cancer Enjoy the reading: https://lnkd.in/dGqQPpdW